First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Kohei Shitara(National Cancer Center Hospital East), Markus Moehler(Johannes Gutenberg University Mainz), Marcelo Garrido, Pamela Salman(Fundación Arturo López Pérez), Lin Shen(Peking University), Lucjan Wyrwicz(Centrum Onkologii), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Tomasz Skoczylas(Medical University of Lublin), Arinilda Campos Bragagnoli(Hospital de Câncer de Barretos), Tianshu Liu(Zhongshan Hospital), Michael Schenker, Patricio Yañez(Universidad de La Frontera), Mustapha Tehfé(Centre Hospitalier de l’Université de Montréal), Rubén Dario Kowalyszyn, Michalis V. Karamouzis(National and Kapodistrian University of Athens), Ricardo Brugés(Instituto Nacional de Cancerología), Thomas Zander(University Hospital Cologne), Roberto Pazo-Cid(Hospital Universitario Miguel Servet), Erika Hitre(National Institute of Oncology), Kynan Feeney(St John of God Murdoch Hospital), James M. Cleary(Dana-Farber Cancer Institute), Valerie Poulart(Bristol-Myers Squibb (United States)), Dana Cullen(Bristol-Myers Squibb (United States)), Ming Lei(Bristol-Myers Squibb (United States)), Hong Xiao(Bristol-Myers Squibb (United States)), Kaoru Kondo(Bristol-Myers Squibb (United States)), Mingshun Li(Bristol-Myers Squibb (United States)), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center)
Cited by 2,884Open Access
Abstract
Related Papers
Integrated genomic characterization of oesophageal carcinoma
Young Soo Park, Jihun Kim , Rebecca Carlsen et al.|Nature|2017|1.8k